Pre-market hot trades in US stocks: Progressive pre-market down 5.46%; Sterling Infrastructure pre-market up 3.29%

Pre-market Hot Trades in US Stocks

Progressive pre-market down 5.46%. Based on recent key news:

1. On July 15, Progressive released its second-quarter financial report showing a GAAP earnings per share of $5.67, exceeding expectations by $0.37, but net premium income was $21.07 billion, falling short of expectations by $190 million. This result heightened market concerns about its profitability, putting pressure on the stock price.

2. On July 15, ongoing inflationary pressures led to rising costs for auto parts, labor, and healthcare, increasing the average cost per claim, which may result in loss costs exceeding premium growth, compressing underwriting profit margins. This situation raised investor concerns about future profitability.

3. On July 14, Progressive announced that the final dividend distribution for its BDR program would be R$0.17 per BDR, with a payment date of July 16. This news failed to boost market confidence as investors remained cautious about its overall financial health. The insurance industry faces inflation and regulatory pressures.

Sterling Infrastructure pre-market up 3.29%. No significant news recently; trading is active with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news

Top Gainers in US Pre-market Stocks

Jet.AI pre-market up 855.36%. Based on recent news,

1. On July 13, Jet.AI completed its merger with flyExclusive. The merger was approved at a special shareholder meeting, marking a collaboration between two key companies, which had a positive impact on the market.

2. On July 14, Jet.AI released its latest financial expectations. Earnings per share expectations were raised from $0.75 to $1.00, although revenue expectations were lowered from $2.23 million to $1.10 million, the market remains optimistic about its performance.

3. On July 15, analysts maintained a buy rating. Maxim Group lowered the target price to $80 but still gave a buy rating, further boosting market confidence. The tech sector has performed strongly recently, with significant capital inflows.

VivoSim Labs pre-market up 134.79%. Based on recent key news:

1. On July 15, VivoSim Labs announced its revenue expectations for fiscal year 2027 to grow over 500% and disclosed receiving a $5 million milestone payment from Eli Lilly. This revenue guidance and payment solidified VivoSim's position in the field of innovative preclinical safety solutions, driving a significant increase in stock price.

2. On July 15, VivoSim Labs' management reduced the number of R&D and SG&A personnel, cutting R&D expenses by 17% and increasing consulting expenses to expand commercial service capabilities. These measures help the company optimize its cost structure and enhance market competitiveness On July 14th, VivoSim Labs detailed its future revenue expectations from service contracts and customized toxicology products in its 10-K annual report. These forward-looking statements provided confidence to investors, further driving up the stock price. The rising demand in the biotechnology industry has propelled the stock price upward.

Ernexa Therapeutics pre-market rose by 69.61%. Based on recent key news:

1. On July 15th, Ernexa Therapeutics' ERNA-101 combination data was successfully replicated in a larger-scale preclinical study. This achievement has bolstered the company's confidence in advancing the New Drug Application (IND) process, significantly driving up the stock price.

2. No other significant news recently. The biotechnology industry has been active lately